


Healthcare | Small Cap
Neuland Laboratories Ltd. demonstrates exceptional financial health, driven by outstanding profitability and remarkable growth. The company excels at converting revenue into profit and is expanding its sales and earnings at a very high rate. Its financial foundation is extremely solid, with very little reliance on debt, which significantly reduces long-term risks. Shareholders have benefited from strong growth in earnings and dividends. The main area of concern is operational efficiency; the company is slow in selling its inventory and collecting payments, and it does not generate as much sales from its assets as it could. While it has an adequate ability to meet its short-term bills, its cash generation from operations is a weaker point. The outlook is positive due to strong growth and profitability, but its future performance also depends on how well it manages its assets.
Neuland Laboratories Ltd. demonstrates exceptional financial health, driven by outstanding profitability and remarkable growth. The company excels at converting revenue into profit and is expanding its sales and earnings at a very high rate. Its financial foundation is extremely solid, with very little reliance on debt, which significantly reduces long-term risks. Shareholders have benefited from strong growth in earnings and dividends. The main area of concern is operational efficiency; the company is slow in selling its inventory and collecting payments, and it does not generate as much sales from its assets as it could. While it has an adequate ability to meet its short-term bills, its cash generation from operations is a weaker point. The outlook is positive due to strong growth and profitability, but its future performance also depends on how well it manages its assets.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
76.12
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
75.93
P/B RATIO
14.75
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
13.63
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
1.96
EV/EBITDA RATIO
45.43
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹21543 as on Aug 6, 2026.
The company is demonstrating excellent and robust growth across the board. It has achieved very high rates of expansion in its revenue, operating profits, and net income. This rapid growth is a clear indicator of strong market demand for its offerings and successful execution of its business strategy. While projections show some volatility with a dip in 2025, the overall trend points to a powerful growth trajectory, which is a key strength.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 1.49 | 25.24 | 30.9 | -5.26 | 36.97 |
| Operating Profit Growth Rate | -2.04 | 89.58 | 69.6 | -28.51 | 73.41 |
| Earnings Per Share (EPS) Growth | -20.86 | 156.23 | 83.52 | -13.32 | 39.94 |
| Asset Growth Rate | 4.38 | 14.24 | 16.01 | 18.93 | 34.4 |
| Net Income Growth Rate | -20.99 | 156.25 | 82.93 | -13.33 | 40 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 41.83 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 75.93 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 34.93 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 41.06 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.60 | 24.31 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 39.72 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Syngene International Ltd | 7.16 | 50.86 | Overvalued | 918.00 | 7.55 | 317.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 30.92 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Piramal Pharma Ltd | 5.83 | -85.00 | Neutral | 922.00 | 5.26 | -326.00 |
| 11 | Jubilant Pharmova Ltd | 5.71 | 37.02 | Neutral | 1260.00 | 1.25 | 398.00 |
| 12 | Natco Pharma Ltd | 5.69 | 11.52 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 13 | Wockhardt Ltd | 5.07 | 150.65 | Neutral | 652.00 | 19.51 | 199.00 |
| 14 | Pfizer Ltd | 3.45 | 48.81 | Neutral | -82.00 | 157.92 | 300.00 |
| 15 | Procter & Gamble Health Ltd | 3.45 | 30.81 | Neutral | 457.00 | 196.94 | 327.00 |
| 16 | Sanofi India Ltd | 3.45 | 18.66 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral